Shuji Murakami

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 44

Top Topics

Squamous Cell Carcinoma

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Japanese journal of clinical oncology

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis. Cancer medicine 13 (7) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer (2024)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, Kyoichi Kaira, Toshiyuki Harada, Daizo Kishino, Yuichi Takiguchi, Tsuneo Shimokawa, Katsuyuki Kiura, Natsumi Yamashita, Hiroaki Okamoto
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). Japanese journal of clinical oncology 54 (7) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, Tetsuro Kondo, Shuji Murakami, Yoshimasa Shiraishi, Hisao Imai, Daijiro Harada, Kazutoshi Isobe, Hidetoshi Itani, Saori Takata, Kazuyoshi Kuwano, Yuki Misumi, Satoshi Ikeda, Tetsuhiko Asao, Naoki Furuya, Shinobu Hosokawa, Yumiko Kobayashi, Yuichi Takiguchi, Hiroaki Okamoto
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study). Clinical cancer research : an official journal of the American Association for Cancer Research 30 (6) (2024)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, Kyoichi Kaira, Toshiyuki Harada, Daizo Kishino, Yuichi Takiguchi, Tsuneo Shimokawa, Katsuyuki Kiura, Natsumi Yamashita, Hiroaki Okamoto
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). Japanese journal of clinical oncology (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Terufumi Kato, Tetsuro Kondo, Huihui Xiang, Rika Kasajima, Hidetomo Himuro, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Yohei Miyagi, Haruhiro Saito, Koichi Azuma, Shuichiro Uehara, Tetsuro Sasada
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Biomedicines 12 (8) (2024)
Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis. Cancer medicine 13 (7) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, Tetsuro Kondo, Shuji Murakami, Yoshimasa Shiraishi, Hisao Imai, Daijiro Harada, Kazutoshi Isobe, Hidetoshi Itani, Saori Takata, Kazuyoshi Kuwano, Yuki Misumi, Satoshi Ikeda, Tetsuhiko Asao, Naoki Furuya, Shinobu Hosokawa, Yumiko Kobayashi, Yuichi Takiguchi, Hiroaki Okamoto
Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study). Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Naoko Shigeta, Shuji Murakami, Tomoyuki Yokose, Tetsuya Isaka, Kanako Shinada, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe, Haruhiro Saito, Hiroyuki Ito
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer. Thoracic cancer 15 (17) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications (2024)
Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Terufumi Kato, Tetsuro Kondo, Huihui Xiang, Rika Kasajima, Hidetomo Himuro, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Yohei Miyagi, Haruhiro Saito, Koichi Azuma, Shuichiro Uehara, Tetsuro Sasada
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Biomedicines 12 (8) (2024)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, Kyoichi Kaira, Toshiyuki Harada, Daizo Kishino, Yuichi Takiguchi, Tsuneo Shimokawa, Katsuyuki Kiura, Natsumi Yamashita, Hiroaki Okamoto
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). Japanese journal of clinical oncology 54 (7) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, Kyoichi Kaira, Toshiyuki Harada, Daizo Kishino, Yuichi Takiguchi, Tsuneo Shimokawa, Katsuyuki Kiura, Natsumi Yamashita, Hiroaki Okamoto
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL). Japanese journal of clinical oncology 54 (7) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 15 (6) (2024)
Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki Ito
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer (2024)
Chihiro Maeda, Kanako Shinada, Shuji Murakami, Haruhiro Saito
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review. Thoracic cancer (2023)
Yusuke Okuma, Shogo Nomura, Kiichiro Ninomiya, Hiroshi Gyotoku, Shuji Murakami, Yoshihito Kogure, Daijiro Harada, Kyoichi Okishio, Hiroaki Okamoto, Yasushi Goto
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study). Future oncology (London, England) (2023)
Seigo Katakura, Shuji Murakami
Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert review of anticancer therapy 22 (9) (2022)
Ryota Ushio, Shuji Murakami, Haruhiro Saito
Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal of clinical medicine 11 (7) (2022)
Shuji Murakami, Tomoyuki Yokose, Kanako Shinada, Testuya Isaka, Kengo Katakura, Ryouta Ushio, Tetsuro Kondo, Terufumi Kato, Hiroyuki Ito, Haruhiro Saito
Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. Thoracic cancer 13 (22) (2022)
Yuji Shibata, Shuji Murakami, Terufumi Kato
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. Expert opinion on drug safety 20 (5) (2021)
Kanako Shinada, Shuji Murakami, Daisaku Yoshida, Haruhiro Saito
Radiation recall pneumonitis after COVID-19 vaccination. Thoracic cancer (2021)
Kanako Shinada, Shuji Murakami, Hideyasu Sugimoto, Haruhiro Saito
Acute eosinophilic pneumonia after changing dosing schedule of nivolumab. Japanese journal of clinical oncology 51 (12) (2021)
Yuji Shibata, Shuji Murakami
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. Expert opinion on drug safety 19 (6) (2020)
Mitsuhiro Moda, Haruhiro Saito, Terufumi Kato, Ryo Usui, Tetsuro Kondo, Yoshiro Nakahara, Shuji Murakami, Kouji Yamamoto, Kouzo Yamada
Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Thoracic cancer 11 (12) (2020)
Takaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, Jun Sato, Ryo Morita, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. Thoracic cancer 11 (4) (2020)
Saki Manabe, Rika Kasajima, Shuji Murakami, Yohei Miyagi, Tomoyuki Yokose, Tetsuro Kondo, Haruhiro Saito, Hiroyuki Ito, Takeshi Kaneko, Kouzo Yamada
Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. Thoracic cancer 11 (8) (2020)
Shuji Murakami, Ryota Shibaki, Yuji Matsumoto, Tatsuya Yoshida, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thoracic cancer 11 (12) (2020)
Daiji Nemoto, Tomoyuki Yokose, Kayoko Katayama, Shuji Murakami, Terufumi Kato, Haruhiro Saito, Masaki Suzuki, Daisuke Eriguchi, Joji Samejima, Takuya Nagashima, Hiroyuki Ito, Kouzo Yamada, Haruhiko Nakayama, Munetaka Masuda
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples. Thoracic cancer 12 (2) (2020)
Yuki Shinno, Yasushi Goto, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Mixed response to osimertinib and the beneficial effects of additional local therapy. Thoracic cancer 10 (4) (2019)
Shuji Murakami
Durvalumab for the treatment of non-small cell lung cancer. Expert review of anticancer therapy 19 (12) (2019)
Nobumasa Tamura, Hidehito Horinouchi, Katsutoshi Sekine, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer. Thoracic cancer 10 (5) (2019)
Ryota Shibaki, Shuji Murakami, Yuki Shinno, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noriko Motoi, Noboru Yamamoto, Yuichiro Ohe
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. Thoracic cancer 10 (4) (2019)
Ryota Shibaki, Shuji Murakami, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Nobuyuki Yamamoto, Noriko Motoi, Masahiko Kusumoto, Noboru Yamamoto, Yuichiro Ohe
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Medical oncology (Northwood, London, England) 36 (6) (2019)
Ryota Shibaki, Shuji Murakami, Yuji Matsumoto, Tatsuya Yoshida, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Nobuyuki Yamamoto, Masahiko Kusumoto, Noboru Yamamoto, Yuichiro Ohe
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer immunology, immunotherapy : CII 69 (1) (2019)